tbuckley/cabot-search huggingface dataset:
DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Natalie S. Callander, Vincent Ribrag, Paul G. Richardson, Ajay K. Nooka, Kevin Song, Katarina Uttervall, Monique C. Minnema, Katja Weisel, Hang Quach, Chang-Ki Min, Marc S. Ballas, Xiaofang Li, Nirav Ratia, Morrys Kaisermann, Beata Holkova, Suzanne Trudel
Journal: Blood (2021)
Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk
Authors: Guldane Cengiz Seval, Klara Dalva, Dilek Oz, Sule Mine Bakanay, Ender Soydan, Gunhan Gurman, Osman Ilhan, Meral Beksac
Journal: Blood (2021)
Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms
Authors: Maher Albitar, Andrew Ip, Andre H. Goy, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Andrew L. Pecora, Jamie Koprivnikar, James K McCloskey
Journal: Blood (2021)
Abstract 9544: Physical Activity in Individuals With Hypertrophic Cardiomyopathy: Baseline Data From the Prospective "Lifestyle and Exercise in Hcm" (live-hcm) Study
Authors: Rachel Lampert, Michael J Ackerman, Bradley S Marino, Matthew Burg, Barbara Ainsworth, Lisa Salberg, Maite Tome, Seshadri Balaji, Carolyn Ho, Richard J Czosek, Cynthia James, Michael Emery, Robert Cooper, Martijn Bos, Jeffrey B Geske, Lubna Choudhury, Susan P Etheridge, Ashwin K Lal, James S Ware, Anne M Dubin, Belinda Gray, Silvana M Molossi, Martin S Maron, Sara Saberi, Daniel L Jacoby, Benjamin W Eidem, Kimberly Harmon, Kevin Hall, Brian Olshansky, Mark S Link, Ian Law, Elizabeth V Saarel, N A Estes, Barry Maron, David S Cannom, Fangyong Li, Kaylie Briske, Laura Simone, Cheryl Barth, Maryann Concannon, Sharlene Day
Journal: Circulation (2021)

Introduction: Safety of vigorous exercise for individuals with appropriately-treated HCM remains debated. Physical activity practices in this population have not been described. The objective of this report is to describe physical activity pattern in HCM patients. Long term follow up which is ongoing will determine safety of vigorous exercise. Methods: The NIH-funded LIVE-HCM study prospectively enrolled individuals age 8-60 years with clinically overt HCM or patients with a positive genetic test for sarcomeric HCM. Participants (or parents, for children) answered surveys describing activity patterns. Vigorous exercise was defined as &gt; 6 METS for &gt; 60 hours per year. Clinical and demographic data were derived from medical record review. Results: Among 1798 participants, 745 (41%) reported exercising vigorously, including 296 competitive athletes, with 59 at high-school or college varsity level, 770 (43%) were exercising at moderate, and 283 (16%) at low levels. Of those working, 6% described jobs more active than walking, including 16 in protective services, and 11 in sports/coaching. Clinical/demographic data including imaging characteristics and treatments, are shown in Table, and were mostly similar amongst the exercise-groups. Conclusions: Many patients with HCM are engaged in vigorous exercise including competitive athletics. Prospective follow-up of this cohort is ongoing. Comparison of arrhythmic outcomes outcomes in vigorous exercisers vs moderate/low level exercisers will help determine the safety of exercise in HCM patients.
Abstract 9041: Provider Evaluation for Selection of Evidence-Based Therapies to Reduce Cardiovascular Complications in Patients With Type 2 Diabetes Mellitus Study - Primary Results of the PREFER-DM Study
Authors: Abhinav Sharma, Marat Fudim, Stephen J Greene, Harriette G Van Spall, Shelley Zieroth, Subodh Verma, Muthiah Vaduganathan, Jonathan Pak, Renato D Lopes
Journal: Circulation (2021)

Introduction: The attributes that health care providers (HCPs) consider in selecting oral antihyperglycemic agents in the treatment of diabetes are not well understood. Methods: In the PREFER-DM study, we used conjoint analysis to evaluate the drug attributes preferred by HCPs toward 3 oral antihyperglycemic drugs: empagliflozin 25 mg (SGLT2i), oral semaglutide 14 mg (GLP-1 RA) and sitagliptin 100 mg (DPP-4 inhibitor). HCPs in the US who regularly treat patients with T2DM were sent an online survey via email; those who participated were asked to select from 6 hypothetical, blinded pair-wise drug profile comparisons of different drug benefits and side effects/risk attributes. Attributes in the survey were derived from published trials and FDA labeling data. The relative importance of one attribute relative to another was calculated. Results: The PREFER-DM survey was distributed to 12,806 HCPs and 1052 valid surveys were completed (365 [35%] primary care physicians, 350 [33%] endocrinologists, 337 [32%] cardiologists). Risk reduction of cardiovascular death was the most important perceived attribute (z-test P &lt;0.05; Figure). Attributes of reduction in heart failure, risk of nausea/vomiting, decreasing progression of renal disease, and weight reduction were considered to have similar importance. The attributes least selected by HCPs were food and medication restriction and A1c lowering (both had similar importance) followed by risk of diabetic ketoacidosis, risk of genital infection, and avoidance of severe hypoglycemia. The relative ordering of attributes remained consistent across specialties (Figure). Conclusion: HCPs across specialities prefer oral antihyperglycemic drug attributes associated with CV risk reduction over side effect profile, tolerability, and adverse outcomes. Whether these preferences translate to prescription patterns and patient acceptance of oral antihyperglycemic drugs in clinical settings remains to be investigated.
ARID1A Controls a Novel Transcriptional Network Regulating FAS in Follicular Lymphoma
Authors: Martina Antoniolli, Maria Solovey, Deepak Bararia, Carolin Dorothea Strobl, William David Keay, Johannes Adrian Hildebrand, Michael Heide, Verena Passerini, Lucas Wange, Wolfgang Enard, Susanne Thieme, Helmut Blum, Martina Rudelius, Sebastian Bultmann, Heinrich Leonhardt, Marion Subklewe, Michael von Bergwelt, Maria Colomé-Tatché, Oliver Weigert
Journal: Blood (2021)
Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma after Donor-Derived CD7- Chimeric Antigen Receptor T-Cell Therapy
Authors: Zhihui Li, Xiaojuan Peng, Xiaopei Wen, Jing Li, Yanzhi Song, Teng Xu, Tong Wu
Journal: Blood (2021)
Contemporary Clinical Management and Course of ACUTE Pulmonary Embolism: The COPE Study
Authors: Cecilia Becattini, Giancarlo Agnelli, Aldo P Maggioni, Francesco Dentali, Andrea Fabbri, Iolanda Enea, Fulvio Pomero, Maria P Ruggeri, Andrea Di Lenarda, Ludovica A Cimini, Giuseppe Pepe, Susanna Cozzio, Michele Diamanti, Simone Vanni, Donata Lucci, Michele M Gulizia
Journal: Blood (2021)
Improved Gene Therapy for Metachromatic Leukodystrophy
Authors: Lucas Tricoli, Adeline Vanderver, Laura Adang, Maxwell Chappell, Laura Breda, Naoto Tanaka, Michael Triebwasser, David Wenger, Danuta Jadwiga Jarocha, Amaliris Guerra, Lars Schlotawa, Karthikeyan Radhakrishnan, Rebecca Ahrens-Nicklas, Peter Kurre, Stephanie Hurwitz, Stefano Rivella
Journal: Blood (2021)
Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
Authors: Nina Shah, Nikhil C. Munshi, Jesús G. Berdeja, Sundar Jagannath, Olivia Finney, Nathan Martin, Amit Agarwal, Everton Rowe, Timothy B. Campbell, Jesús F. San-Miguel
Journal: Blood (2021)
Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq
Authors: Karamjeet S. Sandhu, Ketevan Gendzekhadze, Dongyun Yang, Ryotaro Nakamura, Sally Mokhtari, Monzr M. Al Malki, Haris Ali, Amandeep Salhotra, Stephen J Forman, Medhat Askar, John Altin
Journal: Blood (2021)
Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United States, July 2020–July 2021
Authors: Geoffrey French, Mary Hulse, Debbie Nguyen, Katharine Sobotka, Kaitlyn Webster, Josh Corman, Brago Aboagye-Nyame, Marc Dion, Moira Johnson, Benjamin Zalinger, Maria Ewing
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Surges in COVID-19 cases have stressed hospital systems, negatively affected health care and public health infrastructures, and degraded national critical functions (1,2).Resource limitations, such as available hospital space, staffing, and supplies led some facilities to adopt crisis standards of care, the most extreme operating condition for hospitals, in which the focus of medical decision-making shifted from achieving the best outcomes for individual patients to addressing the immediate care needs of larger groups of patients (3).When hospitals deviated from conventional standards of care, many preventive and elective procedures were suspended, leading to the progression of serious conditions among some persons who would have benefitted from earlier diagnosis and intervention (4).During March-May 2020, U.S. emergency department visits declined by 23% for heart attacks, 20% for strokes, and 10% for diabetic emergencies (5).The Cybersecurity & Infrastructure Security Agency (CISA) COVID Task Force* examined the relationship between hospital strain and excess deaths during July 4, 2020-July 10, 2021, to assess the impact of COVID-19 surges on hospital system operations and potential effects on other critical infrastructure sectors and national critical functions.The study period included the months during which the highly transmissible SARS-CoV-2 B.1.617.2 (Delta) variant became predominant in the United States.† The negative binomial regression model used to calculate estimated deaths predicted that, if intensive care unit (ICU) bed use nationwide reached 75% capacity an estimated 12,000 additional excess deaths would occur nationally over the next 2 weeks.As hospitals exceed 100% ICU bed capacity, 80,000 excess deaths would be expected in the following 2 weeks.This analysis indicates the importance of controlling case growth and subsequent hospitalizations before severe strain.State, local, tribal, and territorial leaders could evaluate ways to reduce strain on public health and health care infrastructures, including implementing interventions to reduce overall disease prevalence such as vaccination and other prevention strategies, as well as ways to expand or enhance capacity during times of high disease prevalence.* The CISA COVID Task Force executes CISA operations in support of the federal COVID-19 response.This includes conducting analyses of COVID-19related disruptions of national critical functions, including supply chain disruptions and misinformation activity.In addition, the Task Force leverages CISA's capabilities, services, and relationships to maintain sustained engagement with health care and public health providers.
<i>Single Cell RNA Sequencing Driven Characterization of Rare B/Myeloid and T/Myeloid Mixed Phenotype Acute Leukemia</i>
Authors: Hope L Mumme, Swati S Bhasin, Beena E Thomas, Deborah DeRyckere, Sharon M. Castellino, Douglas K Graham, Sunil S. Raikar, Manoj Bhasin
Journal: Blood (2021)
Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
Authors: Sheila K Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S. Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S. Uldrick, Frits van Rhee, David C Fajgenbaum
Journal: Blood (2021)
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial
Authors: Tanuja Chitnis, Brenda Banwell, Ludwig Kappos, Douglas L Arnold, Kivilcim Gücüyener, Kumaran Deiva, Natalia Skripchenko, Li-Ying Cui, Stephane Saubadu, Wenruo Hu, Myriam Benamor, Annaig Le-Halpere, Philippe Truffinet, Marc Tardieu, Benedicte Dubois, Helene Verhelst, Veneta Bojinova-Tchamova, Jean Mah, Li-Ying Cui, Fang Fang, Yunpeng Hao, Li Jiang, Ling Li, Ding'An Mao, Wei Qiu, Guojun Tan, Ye Wu, Meini Zhang, Hongyu Zhou, Shuizhen Zhou, Katrin Gross-Paju, Emmanuel Cheuret, Kumaran Deiva, Giles Edan, Sandra Vukusic, George Chrousos, Dimitrios Zafeiriou, Anat Achiron, Adi Vaknin-Dembinsky, Bassem Yamout, Jurate Laurynaitiene, Nerija Vaiciene-Magistris, Vladimir Bojkovski, Vesna Trajkova, Sana Chaouki, Najib Kissani, Rinze Neuteboom, Filipe Palavra, Anna Belova, Alexey Boyko, Evgeny Evdoshenko, Ekaterina Kairbekova, Nadezhda Malkova, Maria Shumilina, Natalya Skripchenko, Dimitrije Nikolic, Jose Meca-Lallana, Chahnez Charfi Triki, Mhiri Chokri, Riadh Gouider, Banu Anlar, Kivilcim Gücüyener, Ayse Semra Hiz, Egemen Idiman, Recai Turkoglu, Zuhal Yapici, Unsal Yilmaz, Lyudmyla Tantsura, Nataliia Voloshyna, Ming Lim, Evangeline Wassmer, Mark Cascione, Tanuja Chitnis, Christopher LaGanke, Kevin Rathke, John Scagnelli
Journal: The Lancet Neurology (2021)
Stenosing flexor tenosynovitis of the hand (trigger finger)
Authors: Jorge Eduardo Molina Ortega, Carlos Gargollo Orvañanos, Esteban Israel Campos Serna, Mauricio De la Concha Tiznado
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Trigger finger is the second cause of consultation with the hand surgeon. In 2009, Kerrigan published a strategy for the treatment of this pathology, which consists of two infiltrations with corticosteroids in the sheath of the flexor tendons at the level of the A1 pulley, followed by percutaneous or open surgical release, following the algorithm described by the author. 140 files that met the inclusion criteria were analyzed. It was found that the female gender is the most frequently affected during the sixth decade of life in 46%. The most frequently affected finger is the third, affects the right hand in 44% and both hands in 29%. 91% of the patients received a first infiltration and only 31% of these received a second infiltration. The surgical procedure was decided in 33% of the patients. The longest follow-up was 180 months and the shortest was 3 months with 100% of asymptomatic patients. The algorithm proposed by Kerrigan in the treatment of this pathology is a good strategy that has a high success rate without having to perform a surgical procedure as the first treatment option.
Abstract PO-073: Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice
Authors: Kiyoshi Saeki, Wanglong Qiu, Richard Friedman, Carrie Shawber, Jan Kitajewski, Jianhua Hu, Gloria H. Su
Journal: Cancer Research (2021)

Abstract Expression of the Notch family of receptors are often upregulated in pancreatic ductal adenocarcinoma (PDAC), however, the functional impacts of the Notch signaling network on pancreatic tumorigenesis remain unresolved. In this study, we focused on Notch4, which had not been investigated in PDAC. Leveraging the conventional Notch4 deficient mouse line and previously established genetically engineered mouse models (GEMM) for PDAC, we generated KC (LSL-KrasG12D;p48-Cre), N4−/−KC (Notch4−/−;LSL-KrasG12D;p48-Cre), PKC (p16flox/flox;LSL-KrasG12D;p48-Cre), and N4−/−PKC GEMMs (Notch4−/−; p16flox/lox;LSL-KrasG12D;p48-Cre). We performed caerulein treatment in both KC and N4−/−KC mice, and compared the development of acinar to ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) between them. The ADM/PanIN lesions were significantly smaller in the N4−/−KC than in the KC GEMM (p=0.01), suggesting that Notch4 deficiency attenuated early pancreatic tumorigenesis. This in vivo result was confirmed by in vitro ADM induction of the explant cultures of mouse pancreatic acinar cells. The number of ADM structures in the N4−/−KC acinar cultures was significantly lower than the KC acinar cultures (p&amp;lt;0.001). To evaluate the role of Notch4 in the later stage of pancreatic tumorigenesis, we compared the histological progression and overall survival between the PKC and N4−/−PKC mice. We found that N4−/−PKC mice had better prognosis (p=0.012) and less tumor burden (PanIN: p=0.018 (2 months), PDAC: p=0.039 (5 months)) compared to the PKC GEMM. RNA-Seq analysis of pancreatic tumor cell lines derived from the PKC and N4−/−PKC GEMMs revealed 408 genes were differentially expressed (FDR&amp;lt;0.05) and the genes related to the NGF processing as novel downstream effectors of the Notch4 signaling pathway(p&amp;lt;0.001). Our study is a novel biological investigation that demonstrated that Notch4 signaling possesses tumor promoting function in pancreatic tumorigenesis. Our study revealed a novel association between the NGF processing pathway and Notch4 signaling in PDAC. Citation Format: Kiyoshi Saeki, Wanglong Qiu, Richard Friedman, Carrie Shawber, Jan Kitajewski, Jianhua Hu, Gloria H. Su. Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-073.
Erythroid Chimerism Measurement As a Predictive Tool of Bone Marrow Transplantation Outcome in Sickle Cell Disease
Authors: Nicolas Hebert, Meghan Perkins, Ivan Sloma, Laura Bencheikh, Florence Beckerich, Rabah Redjoul, Stephane Moutereau, France Pirenne, Sébastien Maury, Gonzalo De Luna, Pablo Bartolucci
Journal: Blood (2021)
A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care
Authors: Divya Koura, Dimitrios Tzachanis, Edward D. Ball, Caitlin Costello, Aaron M Goodman, James K. Mangan, Carolyn Mulroney, Joseph Maroge, Michelle Padilla, Peggy Breslin, Jodi Garrett, Kimberly McConnell
Journal: Blood (2021)
Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances
Authors: Giulia Cheloni, Marzia Capelletti, Daniela Torres, Poorva Bindal, Jessica J. Liegel, Dina Stroopinsky, Lina Bisharat, Maryam Rahimian, Seo Yeon Yoo, Joshua Hauser, Anita G. Koshy, Kenel Dufort, John G. Clohessy, Donald Kufe, Maria Themeli, Jacalyn Rosenblatt, Michel Sadelain, David Avigan
Journal: Blood (2021)
Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse
Authors: Jessica J. Liegel, Poorva Bindal, Richard M. Stone, Robert J. Soiffer, Dina Stroopinsky, Giulia Cheloni, Lina Bisharat, Daniela Torres, Maryam Rahimian, Seo Yeon Yoo, Emma K. Logan, Pavania Elavalakanar, Hassan El Banna, Joshua Hauser, Anita G. Koshy, Rizwan Romee, Vincent T. Ho, Donna S. Neuberg, Yiwen Liu, Lourdes M. Mendez, Ajoy L. Dias, Benjamin L. Ebert, Donald Kufe, David Avigan, Jacalyn Rosenblatt
Journal: Blood (2021)
Myeloid-Biased HSC Require Semaphorin4a from the Bone Marrow Niche for Self-Renewal Under Stress and Life-Long Persistence
Authors: Dorsa Toghani, Sharon Zeng, Elmir Mahammadov, Edie Crosse, Amogh Pradeep, Nicola Wilson, Sarah Kinston, Sonia Rodriguez, Negar Seyedhassantehrani, David Gravano, Christian Burns, Stefan Radtke, Nadia Carlesso, Hans-Peter Kiem, David T. Scadden, Eric Pietras, Bertie Gottgens, Antonio Scialdone, Joel Spencer, Lev Silberstein
Journal: Blood (2021)
Abstract 9490: Home-Based Cardiac Rehabilitation During COVID-19
Authors: Smitha Ganeshan, Crystal Tse, Alexis Beatty
Journal: Circulation (2021)

Introduction: Cardiac rehabilitation (CR) reduces morbidity, hospitalizations, and mortality. Increasingly, digital tools have augmented the ease of delivering programs outside of the traditional rehabilitation center setting. Because of the need for distancing during the COVID-19 pandemic, many cardiac rehabilitation (CR) centers suspended in-person services and pivoted to home-based CR (HBCR). Hypothesis: In this study, we qualitatively evaluated the implementation of HBCR, which included weekly phone or video visits for individualized exercise plans, nutrition and health education counseling, wellness sessions, and optional mobile phone applications. Methods: Patient participants and staff members (physician, nurses, exercise physiologists, dietician, administrative staff) participated in semi-structured interviews. Two independent reviewers coded interview transcripts for emergent themes and pre-specified themes from the Theory of Planned Behavior, Unified Theory of Acceptance and Use of Technology, and the Consolidated Framework for Implementation Research. Results: A total of 12 patients and 7 staff were interviewed. Narrative descriptions highlighted the isolation, fear, and disruption of life activities during COVID-19. Key facilitators of the HBCR patient experience included strong relationships with staff who served as coaches and sources of accountability and the ability of HBCR to deliver an individually tailored experience within a patient’s home. Important organizational factors for implementation included leadership buy-in, culture of change, and support for staff. Though technology tools facilitated communication and accountability, not all participants embraced technology and some reported challenges with use. Participants in the modified program (N=57) experience 60.4m (+/- 50.4 SD) improvement in 6 minute walk distance. At the conclusion of the program, 45/62 (72.6%) achieved BP control &lt;130/80. Conclusions: Individually tailored HBCR can facilitate access for patients to participate outside of a CR center. Ongoing research is needed to understand the long-term outcomes of flexible delivery models that may include both in-person and remote visits, and the role of technology in these models.
Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma
Authors: Jakoba J Eertink, Gerben J.C Zwezerijnen, Sanne E Wiegers, Martine E.D Chamuleau, Pieternella Lugtenburg, Daphne De Jong, Bauke Ylstra, Matias Mendeville, Ulrich Dührsen, Andreas Hüttmann, Christine Schmitz, Julia Richter, Wolfram Klapper, Otto S Hoekstra, Henrica C.W de Vet, Ronald Boellaard, Josée M Zijlstra
Journal: Blood (2021)
Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer
Authors: Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, Ganessan Kichenadasse
Journal: Journal of the National Comprehensive Cancer Network (2021)

PARP inhibitors are orally administered antineoplastic agents that affect the homologous recombination (HR) repair pathway, and are approved by the FDA for the treatment of ovarian, breast, pancreatic, and prostate cancers. This report presents a case of recurrent endometrial carcinoma occurring in a woman with a germline pathogenic PALB2 whole-exon deletion. This uncommon finding in a patient with endometrial carcinoma provided the opportunity to use a management strategy of PARP inhibition with olaparib, resulting in a prolonged response to treatment; however, disease progression eventually occurred. Further studies are required to elucidate the mechanisms underlying resistance to PARP inhibition, and the potential future treatment options in this setting. Current recommendations for risk management of female carriers of PALB2 variants focus on breast and ovarian cancer risk. This case raises the additional question of a potential role for risk-reducing hysterectomy in female carriers of PALB2 variants.
Long-term Risk of Cognitive Impairment and Dementia Following Bilateral Oophorectomy in Premenopausal Women—Time to Rethink Policies?
Authors: Marios K. Georgakis, Eleni T. Petridou
Journal: JAMA Network Open (2021)

Walter A. Rocca, MD, MPH; Christine M. Lohse, MS; Carin Y. Smith, BS; Julie A. Fields, PhD; Mary M. Machulda, PhD; Michelle M. Mielke, PhD